Bristol-Myers Squibb (NYSE:BMY) Shares Sold by Piscataqua Savings Bank

Piscataqua Savings Bank decreased its stake in Bristol-Myers Squibb (NYSE:BMY) by 6.5% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,684 shares of the biopharmaceutical company’s stock after selling 325 shares during the period. Piscataqua Savings Bank’s holdings in Bristol-Myers Squibb were worth $286,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. LaFleur & Godfrey LLC raised its stake in shares of Bristol-Myers Squibb by 3.5% during the 4th quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company’s stock worth $2,463,000 after buying an additional 1,487 shares during the last quarter. Brighton Jones LLC raised its position in shares of Bristol-Myers Squibb by 33.4% during the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company’s stock worth $1,116,000 after purchasing an additional 4,935 shares during the last quarter. Tyche Wealth Partners LLC raised its position in shares of Bristol-Myers Squibb by 20.6% during the 4th quarter. Tyche Wealth Partners LLC now owns 5,729 shares of the biopharmaceutical company’s stock worth $324,000 after purchasing an additional 979 shares during the last quarter. Silver Oak Securities Incorporated raised its holdings in shares of Bristol-Myers Squibb by 76.4% in the fourth quarter. Silver Oak Securities Incorporated now owns 6,997 shares of the biopharmaceutical company’s stock worth $392,000 after acquiring an additional 3,030 shares during the last quarter. Finally, Telos Capital Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 3.7% in the fourth quarter. Telos Capital Management Inc. now owns 110,412 shares of the biopharmaceutical company’s stock worth $6,245,000 after acquiring an additional 3,985 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 4,250 shares of the firm’s stock in a transaction that occurred on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares in the company, valued at approximately $3,973,548.54. This trade represents a 5.36% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.09% of the stock is owned by insiders.

Bristol-Myers Squibb Price Performance

BMY stock opened at $48.42 on Friday. The stock has a 50-day moving average price of $49.34 and a two-hundred day moving average price of $55.06. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $63.33. The company has a current ratio of 1.25, a quick ratio of 1.15 and a debt-to-equity ratio of 2.90. The company has a market cap of $98.54 billion, a PE ratio of -10.95, a price-to-earnings-growth ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.50 by $0.30. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The business had revenue of $11.20 billion during the quarter, compared to analysts’ expectations of $10.77 billion. During the same quarter in the previous year, the business earned ($4.40) EPS. The company’s revenue for the quarter was down 5.6% on a year-over-year basis. As a group, research analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Analyst Upgrades and Downgrades

BMY has been the subject of a number of analyst reports. UBS Group cut their price target on Bristol-Myers Squibb from $60.00 to $54.00 and set a “neutral” rating for the company in a report on Friday, April 11th. Jefferies Financial Group cut their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a “buy” rating for the company in a research note on Wednesday, April 23rd. The Goldman Sachs Group reissued a “neutral” rating and issued a $55.00 price objective (down previously from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Argus raised shares of Bristol-Myers Squibb to a “hold” rating in a research report on Friday, April 25th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $58.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.